Stay updated with breaking news from T Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A new study looked at the whole spectrum of immunological reactions raised by spike and non-spike antigens following Omicron BA.1/BA.2 infections in such individuals, both with and without prior SARS-CoV-2 infection.
A team of researchers from the Cancer Science Institute of Singapore at the National University of Singapore, led by Associate Professor Takaomi Sanda and Dr Lim Fang Qi, has breathed new life into an existing drug—combatting a type of blood cancer called T-cell acute lymphoblastic leukemia, or T-ALL.
Researchers reported that the SARS-CoV-2 Omicron XBB.1.5 variant evades neutralizing response elicited by bivalent vaccine boosters.
In a recent study published in The Lancet Microbe journal, researchers described the effectiveness of a modular capsid virus-like coronavirus disease 2019 (COVID-19) vaccination.
The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.